Tags

Type your tag names separated by a space and hit enter

Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis.
Intern Med. 2012; 51(12):1585-9.IM

Abstract

We report the case of a young woman with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, without tumor, who was successfully treated with rituximab. Because conventional immunotherapy, including corticosteroids, immunoglobulin (IVIg), and plasma exchange showed little improvement in our patient, we introduced another treatment using rituximab. A week after the first administration of rituximab, her symptoms improved gradually and significantly. This case provides in vivo evidence that rituximab is an effective agent for treating anti-NMDAR encephalitis, even in those cases where conventional immunotherapies have been ineffective. Rituximab should be regarded as a beneficial therapeutic agent for this disease.

Links

Publisher Full Text

Authors+Show Affiliations

Ikeguchi R
Department of Neurology, Saitama Red Cross Hospital, Japan. riker715@hotmail.com
Shibuya K
No affiliation info available
Akiyama S
No affiliation info available
Hino S
No affiliation info available
Kubo H
No affiliation info available
Takeda T
No affiliation info available
Shibata N
No affiliation info available
Yamamoto K
No affiliation info available

MeSH

Adrenal Cortex HormonesAnti-N-Methyl-D-Aspartate Receptor EncephalitisAntibodies, Monoclonal, Murine-DerivedElectroencephalographyFemaleHumansImmunoglobulins, IntravenousImmunosuppressive AgentsPlasma ExchangeRituximabYoung Adult

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22728495

Citation

Ikeguchi, Ryotaro, et al. "Rituximab Used Successfully in the Treatment of anti-NMDA Receptor Encephalitis." Internal Medicine (Tokyo, Japan), vol. 51, no. 12, 2012, pp. 1585-9.
Ikeguchi R, Shibuya K, Akiyama S, et al. Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis. Intern Med. 2012;51(12):1585-9.
Ikeguchi, R., Shibuya, K., Akiyama, S., Hino, S., Kubo, H., Takeda, T., Shibata, N., & Yamamoto, K. (2012). Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis. Internal Medicine (Tokyo, Japan), 51(12), 1585-9.
Ikeguchi R, et al. Rituximab Used Successfully in the Treatment of anti-NMDA Receptor Encephalitis. Intern Med. 2012;51(12):1585-9. PubMed PMID: 22728495.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rituximab used successfully in the treatment of anti-NMDA receptor encephalitis. AU - Ikeguchi,Ryotaro, AU - Shibuya,Koichi, AU - Akiyama,Shigeo, AU - Hino,Shuji, AU - Kubo,Hiromasa, AU - Takeda,Takahiro, AU - Shibata,Noriyuki, AU - Yamamoto,Kenji, Y1 - 2012/06/15/ PY - 2012/6/26/entrez PY - 2012/6/26/pubmed PY - 2012/11/14/medline SP - 1585 EP - 9 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 51 IS - 12 N2 - We report the case of a young woman with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, without tumor, who was successfully treated with rituximab. Because conventional immunotherapy, including corticosteroids, immunoglobulin (IVIg), and plasma exchange showed little improvement in our patient, we introduced another treatment using rituximab. A week after the first administration of rituximab, her symptoms improved gradually and significantly. This case provides in vivo evidence that rituximab is an effective agent for treating anti-NMDAR encephalitis, even in those cases where conventional immunotherapies have been ineffective. Rituximab should be regarded as a beneficial therapeutic agent for this disease. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/22728495/Rituximab_used_successfully_in_the_treatment_of_anti_NMDA_receptor_encephalitis_ L2 - https://joi.jlc.jst.go.jp/DN/JST.JSTAGE/internalmedicine/51.6874?from=PubMed DB - PRIME DP - Unbound Medicine ER -